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Top-down proteomics characterizes protein primary structures with unprejudiced descrip-
tions of expressed and processed gene products. Gene sequence polymorphisms, protein
post-translational modifications, and gene sequence errors can all be identified using top-
down proteomics. Saliva offers advantages for proteomic research because of availability and
the noninvasiveness of collection and, for these reasons, is being used to search for disease
biomarkers. The description of natural protein variants, and intra- and inter-individual
polymorphisms, is necessary for a complete description of any proteome, and essential for the
discovery of disease biomarkers. Here, we report a striking example of natural protein variants
with the discovery by top-down proteomics of two new variants of Peptide P-C. Intact mass
measurements, and collisionally activated-, infrared multiphoton-, and electron capture-
dissociation, were used for characterization of the form predicted from the gene sequence with
an average mass 4371 Da, a form postulated to result from a single nucleotide polymorphism
of mass 4372 Da, and another form of mass 4370 Da postulated to arise from a novel protein
sequence polymorphism. While the biological significance of such subtle variations in protein
structure remains unclear, their importance cannot be assigned without their characterization,
as is reported here for one of the major salivary proteins. (J Am Soc Mass Spectrom 2010, 21,
868–877) © 2010 American Society for Mass SpectrometrySaliva is excreted by the parotid, submandibular,sublingual, and Von Ebner’s exocrine glands tolubricate the mouth, initiate digestion, and con-
tribute to the defense of the oral cavity by providing
protection with antibacterial, antifungal, and antiviral
activities [1, 4]. These activities are attributed to pro-
teins and other small molecules excreted in saliva. With
easy availability and a noninvasive collection process,
saliva is a useful fluid to use in the search for disease
biomarkers. Two approaches are being used to charac-
terize the salivary proteome. The first relies on standard
bottom-up proteomic approach with tandem mass
spectrometry (MS/MS) of tryptic peptides to compile a
catalogue of salivary proteins and of predictable post-
translational modifications [2]. However, bottom-up
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doi:10.1016/j.jasms.2010.01.026proteomic strategies suffer from technical problems
such as variable digestion yield, variable peptide extrac-
tion efficiency from gels, missed cleavages, poor recov-
ery of some peptides during liquid chromatography,
and poor ionization efficiency of some peptides, leading
to variable and incomplete coverage of protein se-
quences. In addition, bottom-up experiments only rec-
ognize predicted post-translational modifications, exac-
erbating this problem.
The second approach being used to characterize the
salivary proteome uses a combination of top-down,
with liquid chromatography (LC) fractionation of intact
proteins coupled with intact protein mass measure-
ments, and bottom-up approaches, to more completely
characterize salivary proteins [3]. Provided that pro-
teins can be relatively well separated from each other,
analysis of the intact proteins using top-down strategies
provides an alternative means to fully characterize the
diversity of the human salivary proteome. Different
protein variants are usually defined by their own
unique molecular weight. An intact mass tag (IMT)
refers to the experimentally measured mass of a whole
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modifications [4]. This method has been promoted by
the work of Kelleher and coworkers [5] and is now
becoming an attractive alternative to obtain detailed
information on protein structure [6]. Consequently,
comprehensive saliva proteome characterization must
involve the use of both bottom-up and top-down ap-
proaches to define the different protein variants [3, 7].
The combination of these approaches will eventually
provide an extensive catalogue of salivary proteins with
their detailed molecular characterization.
However, the salivary proteome has some properties
that make it difficult to fully characterize. First is the
presence of protein superfamilies, such as the abundant
proline-rich proteins (PRPs) and histatins in which
many different protein products arise by differential
post-translational processing of a limited number of
gene products. This leads to a high degree of sequence
homology amongst the various products, exacerbated
in some cases by the presence of repetitive sequence
units that require extensive sequence coverage to dis-
tinguish between them. Secondly, salivary proteins are
often subjected to extensive proteolytic processing at
both N- and C-termini before secretion. The resulting
products may be too small to produce the number of
tryptic fragments normally required for unequivocal
bottom-up identification or, as in the case of the PRPs,
bottom-up identification may be compromised because
the juxtaposition of proline and basic residues renders
trypsin ineffective. Third, single nucleotide polymor-
phisms, alternative splicing, and post-translational
modifications all contribute to further increase the het-
erogeneity of human saliva proteins [8]. While the goal
of cataloguing the presence of different salivary gene
products is simply accomplished with bottom-up ap-
proaches, the goal of completing detailed molecular
characterization of these products is more complex.
Castagnola and colleagues used liquid chromatogra-
phy (LC) combined with online electrospray ionization
mass spectrometry (ESI-MS) to characterize the more
abundant lower molecular weight protein variants in
various saliva preparations [9, 10]. By supplementing
low-resolution intact mass measurements obtained on
quadrupole instruments with MS/MS data after prote-
olysis, a good start was made toward documentation of
the processing and modifications of several classes of
salivary proteins (e.g., histatin and statherin), and their
variability between individuals [3, 7, 11–13]. More re-
cently this approach was successfully used by Messana
et al. to elucidate saliva protein trafficking in concert
with post-translational events such as phosphorylation,
sulfation, and cleavage of propeptides [14].
Our goal is to apply top-down mass spectrometry
experiments to characterize human salivary proteins in
significantly greater detail. Here, we report on experi-
ments that distinguish variants of Peptide P-C, an
abundant human salivary protein that is derived from
in vivo cleavage of salivary acidic proline-rich phospho-
proteins 1 and 2 (PRP superfamily), and that is alsocharacterized by the lack of trypsin cleavage site. Acidic
PRPs are thought to be involved in calcium homeostasis
in the oral cavity and act by preventing calcium phos-
phate precipitation that is necessary for maintaining
tooth enamel integrity. Also, recent studies have dem-
onstrated that Peptide P-C can modulate blood glucose
levels after feeding by inducing insulin release and by
restricting glucagon release [15, 16]. The Peptide P-C
variants have a nominal mass in the 4370–4372 Da
range with overlapping isotopomer distributions that
were resolved only with a Fourier-transform ion cyclo-
tron resonance (FTICR) mass spectrometer operating at
750,000 resolving power. Manual data interpretation
was needed to assign the newly reported variants
because they would have been otherwise overlooked by
automated data processing, as their primary structure
was not in the sequence databases.
Experimental
Chemicals
All solvents (HPLC grade and otherwise), buffers, and
reagents [guanidine HCl, acetonitrile, anti-protease
cocktail, trifluoroacetic acid (TFA)] used were pur-
chased from Sigma Aldrich.
Sample Collection
Saliva samples were obtained from five donors who
were recruited for the Human Salivary Proteome
Project. Donors were in good health and exhibited
normal salivary function. Parotid saliva secretions were
harvested using a saliva collector [17] fitted with a
sterile 100 L pipette tip. Stimulation of the salivary
glands was provided by repeated topical application of
a mild solution of citric acid (2%) to the dorsal surface
of the tongue. Care was taken to keep the acid solution
away from the collection area. Collection volumes were
500–2000 L/donor. The collected samples were cen-
trifuged (2600  g, 15 min, 4 °C), and re-centrifuged (20
min) if the supernatant was not clear to the naked eye.
Supernatants were transferred to new containers to
which was promptly added aprotinin (1 L/mL saliva,
10 mg/mL), sodium orthovanadate (3 L/mL saliva,
400 mM), and phenylmethyl sulfonyl fluoride (10
L/mL saliva, 10 mg/mL) before storage at 80 °C.
Sample Fractionation by LCMS
Individual parotid saliva samples (between 500 L and
1 mL) were dried by centrifugal evaporation, re-
dissolved in aqueous guanidine-HCL (6 M, 100 L),
centrifuged (10,000  g, 5 min, room temperature), and
processed by combined liquid chromatography-mass
spectrometry with on-line fraction collection [18] in
which the supernatant was injected onto a polymeric
reversed phase column (Polymer Labs PLRP/S 5 m,
300 Å, 2  150 mm, 40 °C) previously equilibrated in
870 HALGAND ET AL. J Am Soc Mass Spectrom 2010, 21, 868–87795% buffer A, 5% buffer B (A, 0.1% TFA in water; B,
0.1% TFA in acetonitrile), and eluted (150 L/min) with
an increasing percentage of buffer B (min/% B; 0/5,
5/5, 10/20, 70/50, 90/90). The eluent was passed
through a UV detector (280 nm) before a flow splitter
with fused silica capillaries to transfer liquid to an
Ionspray source (50 cm, 50 L/min) and the fraction
collector (25 cm, 100 L/min). Fractions (1 min) were
collected into microcentrifuge tubes and stored at
20 °C for further analysis.
The Ionspray source was connected to a triple quad-
rupole mass spectrometer (API III; Applied Biosys-
tems) tuned and calibrated as described [19], scanning
from m/z 600 to 2300 (orifice voltage ramped with m/z
from 6 to 120, 6 s/scan). Data were processed using
MacSpec 3.3, Hypermass, and BioMultiview 1.3.1 soft-
ware (Applied Biosystems).
High-Resolution Top-Down Mass Spectrometry
and Tandem Mass Spectrometry
These experiments were performed as previously de-
scribed [8] on a 7 Tesla hybrid linear ion trap-FTICR
mass spectrometer (LTQ-FT Ultra, Thermo Fisher Cor-
poration, San Jose, CA, USA) fitted with an off-line
nanospray source. Pooled fractions from the LCMS
experiments, eluting between 19 and 21 min and en-
compassing all the detectable variants of Peptide P-C,
were individually loaded into 2 m i.d. externally-coated
nanospray emitters (New Objective Inc., Woburn, MA,
USA) and directly desorbed/ionized using a spray
voltage of between 1.2 and 1.4 kV (versus the inlet of the
mass spectrometer). These conditions produced a flow
rate of 20–50 nL/min. Ion transmission into the linear
trap and further to the FTICR cell was automatically
controlled to a 2  106 ion count target for both the full
scan- and MS2-FTICR experiments. The m/z resolving
power of the FTICR mass analyzer was set to either
100,000 or 750,000 (defined by m/m50% at m/z 400).
Individual charge states of the multiply protonated
protein molecular ions were selected for isolation and
collisional activation in the linear ion trap, followed by
the detection of the resulting fragments in the FTICR
cell. For FTICR-MS/MS experiments, parameters were
chosen to fragment the full isotopic mass of the 5
charge ion with the view to increase detection of
product ions while checking for homogeneity of the
selected peak. For the collisionally activated dissocia-
tion (CAD) studies, the precursor ions were activated
using 12% to 15% normalized collision energy at the
default activation q-value of 0.25. Additional studies
were conducted in which the precursor ions were
guided to the FTICR cell and further fragmented using
electron capture (ECD) using the following instrument
settings (5% to 10% normalized collision energy, 50 ms
delay, and 10 ms duration) and infrared multiphoton
(IRMPD, instrument settings of 50% normalized colli-
sion energy, 50 ms delay and 20 ms duration) dissoci-ation experiments. In both cases, the fragmentation
efficiency was optimized to maximize product ion sig-
nal intensity. Ion count target was the same for CAD,
IRMPD, and ECD MS/MS experiments with a value of
2  106.
FTICR Data Analysis
FTICR spectra, from an average of 50–500 transient
signals, were examined with a combination of manual
and automatic procedures. Monoisotopic mass lists
(s/n  1.1, fit 0%, remainder 0%, averagine table set to
averagine) were prepared using XtractAll (Xcalibur 2.0,
Thermo Fisher, Bremen, Germany). ProSight PTM
(https://prosightptm.scs.uiuc.edu) and ProSight PC
(Thermo Fisher) software suites were used with a
threshold of 15 ppm and the deltamass feature deacti-
vated, with custom post-translational modifications as
required. Interpretation was a manual, iterative process
as different sequences and post-translational modifica-
tions were independently tested to maximize the num-
ber of product ions matched. Nomenclature for assign-
ment of peptide/protein ions was according to
Roepstorff and Fohlman [20].
P-Score values reflect the match of the proposed
primary structure with the peaklist data; the lower the
score, the higher the confidence in the proposed se-
quence [21]. We also used a manual P-Score that simi-
larly reflects the confidence in data interpretation, but
relies on masses of product ions that matched the
sequence, updated with product ions manually identi-
fied in the MS/MS spectra. Manual P-Scores were
calculated in ProSight PTM using the Manual Single
Protein Mode. Extracted peak lists are provided in the
Supplemental Materials, which can be found in
the electronic version of this article.
Putative Deamidation of Peptide P-C
To determine if Peptide P-C was prone to a time-
dependent deamidation process at residue Q14, an
HPLC fraction containing this material was split into
two equal parts. One part (20% acetonitrile, 0.1% TFA)
was untreated, and the other dried in a vacuum centri-
fuge and re-dissolved in ammonium bicarbonate (pH
7.5). Both parts were incubated for 10 days at 37 °C.
Each day, an aliquot from each was analyzed by record-
ing the MS and CAD MS/MS spectra, and the isotopic
profiles of the b15-product ions were compared.
Results
Peptide P-C is derived from a salivary PRP (PRH1 and
allele PRH2, accession number P02810). PRH1 is easily
identified in bottom-up studies, although these datasets
cannot distinguish between the various products of
PRH1 that accumulate in saliva. Peptide P-C is a pep-
tide with a mass of  4371 Da—outside the mass range
usually employed in bottom-up protocols. It is easily
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Based on the preliminary analyses, a number of factors
suggested micro-heterogeneity within the Peptide P-C
population. These factors included a bimodal elution
profile and a variable charge-state distribution across
this chromatographic peak (data not shown). Conse-
quently, fractions collected concomitant with detection
of the 4371-Da IMT during LC-MS were subjected to
further analysis by top-down MS.
High-resolution (R  100 000 @ m/z 400) intact mass
measurements and the IRMPD MS/MS spectra clearly
confirmed the presence of the known Peptide P-C
sequence with high confidence when the data were
processed automatically with Xtract and ProSight PTM
(Figure 1c and Table 1 of Supplementary Material).
However, by manually comparing experimental and
theoretical isotopomer profiles, the spectra indicated
the presence of both lighter and heavier forms than that
predicted from the known Peptide P-C sequence
(P02810). For example, examination of the pentuply-
charged precursor ion showed a minor isotopomer 1 Da
lighter than the monoisotopic peak (Figure 1a). Further-
more, the isotopomer cluster of signals assigned as a
mixture of doubly-charged b22-NH3 and b21-H2O
IRMPD product ions similarly displayed the presence
of a peak 1 Da lighter than the monoisotopic peak
(Figure 1b). This ion at m/z 1066.0447 was later assigned
to the b21-H2O product ion of the lighter form of
Peptide P-C (Variant 1). At the same time, the isoto-
pomer cluster for the b15 IRMPD product ion presented
an overabundance of the first 13C component, indicat-
ing the presence of a species 1 Da heavier than the
Figure 1. (a) Expanded view of the 5-charged
of 48,000 before LTQFT IRMPD MS/MS fragmen
the predicted isotopomer signals based upon the
O57). A small apparent isotopomer 1 Da lighter t
mark. (b) Expanded view of the isotopomer
produced during IRMPD fragmentation of th
calculated intensity of the predicted isotopomer
b22-NH3 ion (C94 H138 N31 O27). This spectrum r
with the question mark. (c) Sequence coverage
precursor ion at m/z 875.05 matched to the publ
and ProSight PTM software.monoisotopic peak (data not shown). These features led
to further investigations of the possible presence of two
variants of the peptide that differ by the nominal mass
of  1Da.
Additional MS and MS/MS experiments were per-
formed at ultra-high-resolution (R  750,000 at m/z 400)
in an attempt to better resolve the microheterogeneity.
The isotopomer distribution of the molecular ion sig-
nals for the 5-charged ion of Peptide P-C at m/z
875.0459 revealed a mixture of three putative variants
(Figure 2). These forms have measured monoisotopic
masses of 4367.2570 (Variant 1), 4368.1855 (consistent
with residues 123-166 of accession number P02810), and
4369.1696 (Variant 2) Da (Table 1).
To account for the two extra variants, we first pro-
posed the heavier form as due to N-to-D or Q-to-E SNP,
or the possible occurrence of a single deamidation.
D-to-N SNPs have been reported for positions 20 and 66
of PRH1 (Peptide P-C is residues 123-166 of PRH1;
GeneID: 5554) [22, 23]. Although a Q-to-K variant has
also been reported at position 163 within the Peptide
P-C sequence [23], this was considered unlikely in this
sample because such a change was inconsistent with the
mass measurement accuracy available on the FTMS
instrument. The lighter form, Variant 1 (Table 1), has a
significant positive mass defect that is hypothesized to
result from a sequence change eliminating oxygen at-
oms. The explanation for this lighter species was not
immediately apparent, and therefore the deduced pro-
tein sequences from the three calculated open reading
frames of full-length PRH1/2 mRNA sequence (P02810)
containing the Peptide P-C sequence (NM_005042) were
ursor ion at m/z 875.05 recorded at a resolution
n. The asterisks show the calculated intensity of
ental composition for Peptide P-C (C189 H290 N64
he monoisotopic peak is labeled with a question
r of the b22-NH3 and b22-H2O product ions
cursor shown in (a). The asterisks show the
ls based upon the elemental composition for the
s an additional isotopomer 1 Da lighter, labeled
and y-ions observed during IRMPD of the 5
sequence of Peptide P-C (P02810) using Xtractprec
tatio
elem
han t
cluste
e pre
signa
eveal
of b-
ished
three proposed variants overlaid, each normalized to 100% intensity.
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phisms. Predictions of ORFs and their translations were
performed with the Wise2 software from EMBL-EBI
(http://www.ebi.ac.uk/Wise2/), and results obtained
for the C-terminus of the protein corresponding to the
Peptide P-C sequence are displayed in Figure 3. This
revealed the presence of a homologous 16 amino acid
in-frame sequence of Peptide P-C, immediately up-
stream (residues 106-122) of the regular Peptide P-C
sequence (residues 123-140 of 123-166), which only
differs by a short stretch of amino acids with the
replacement of the regular sequence QQGPPP by
PRPPR. This sequence replacement results in a calcu-
lated molecular weight for the Peptide P-C variant of
4367.2386 Da, or 0.9364 Da lighter than the mass calcu-
lated for the regular sequence. This is hypothesized to
explain the presence of Variant 1. Though the genetic
basis of this variant form is obscure at this point, it
is somewhat consistent with previous literature report-
ing saliva protein genetic polymorphism for PRPs.
Table 1 summarizes the three observed forms and their
assigned sequences.
The veracity of these assignments was tested with
additional MS/MS experiments specifically to locate
unique product ions to confirm these sequence assign-
ments. A unique ion is an unambiguously assigned
product ion that cannot be explained by internal frag-
mentation, or loss of water, ammonia etc. Manual
analysis of the IRMPD MS/MS spectrum from the
5-charged precursor cluster at 750,000 resolution
showed some product ions lacking shoulders, such as
product ion y11 (m/z 1120.54), some with a single
satellite peak such as the b41 product ion (m/z 1011.01,
z  4), and some with two additional peaks such as
b42-NH3 product ion (m/z 1028.51, z  4, Figure 4). The
fact that some product ions showed microheterogeneity
while others did not is consistent with the true peptide
microheterogeneity as concluded from Figure 2, and
assuaged concerns that the results were some type of
artefact of the FTICR experiment. However, no unique
ions were found in either the CAD (data not shown) or
IRMPD datasets that allowed unequivocal assignment
of the location of the variant masses. Consequently, the
origin of the Peptide P-C sequence microheterogeneity
was sought from ECD experiments.
The analysis of ECD spectra showed that nearly all
permitted cleavages were observed for the regular and
Variant 2 forms (Tables 2 and 3 of Supplementary
Material, and Figure 5). Diagnostic ions used to assess
the presence of both variants are z•-product ions. At-
tention was paid to the presence of z=-product ions
when the heavier form of Peptide P-C was searched. In
that case, the experimental mass accuracy was sufficient
to distinguish between z=- and z•-product ions from
regular and heavier forms, respectively. The ECD ex-
periments unequivocally confirmed the regular se-
quence and the presence of deamidation/SNP at posi-
tion 14 (Gln) with a P-score of 6  10e79 for Variant 2Figure 2. (a) Mass spectrum of the 5-charged ion of Peptide P-C
at ultra-high-resolution (R  750,000 at m/z 400). The three pro-
posed Peptide P-C species (see Table 1), including the lighter Variant
1 postulated as replacement of QQGPP by PRPPR (1 Da), the
regular sequence of Peptide P-C, and the heavier Variant 2 postu-
lated to arise from deamidation or a SNP ( 1 Da), are respectively
labeled (filled square), (asterisk), and (filled circle). The assignments
are chosen to best account for the observed masses and mass defects.
Experimental monoisotopic molecular weights deduced from the
monoisotopic peak of each species are 4367.2570 Da (theoretical
value: 4367.2386 Da, mass error  0.0184 Da, 4.2 ppm) for Variant 1,
4368.1855 Da (theoretical value: 4368.1750 Da, mass error  0.0105
Da, 2.4 ppm) for the regular form, and 4369.1696 (theoretical value:
4369.1590 Da, mass error  0.0106 Da, 2.4 ppm) for Variant 2,
respectively (see Table 1). (b) Theoretical isotopomer profiles of the(Figure 5, and Table 3 of Supplementary Material). In
QGQ
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value of 7.14 ppm compared to the other searches. This
is attributed to misassignment of monoisotopic versus
13C peaks for the regular and Variant 2 (deamidated/
SNP) forms as a result of incomplete peak lists for the
minor sequence variant.
To distinguish between the occurrence of a deami-
dation process and a SNP, the isotopic profile of the b15
product ion that was used to identify the heavier form
was monitored over several days. Peptide P-C was
placed at 37 °C directly from the HPLC fraction (20%
acetonitrile, acidic pH) or re-dissolved in ammonium
bicarbonate (pH 7.5) after drying. CAD MS/MS spectra
recorded over the following 10 days revealed that the
relative intensity of the 13C peak was unchanged, allow-
ing conclusion that the heavier form likely corresponds
to a SNP rather than a deamidation process. In addition,
the likelihood of such deamidation process occurring
during sample handling/processing was deemed rela-
tively low because the samples were not exposed to
basic pH [24, 25].
Figure 3. Calculated open reading frames (named 1, 2, and
3) from the full DNA sequence (NM_005042.2) of the proline rich
protein (P02810) Residues 106-173 is shown) containing the Pep-
tide P-C sequence (Peptide P-C sequence is residues 123-166,
underlined sequence). Sequence alignment shows the tandem
sequence repeats and reveals the possibilities for sequence recom-
bination due to DNA slippage or alternative splicing. Taking into
account these possibilities, it was postulated that the lighter
Variant 1 could arise by replacement of residues 123-140 with
106-122, altering QQGPPP to PRPPR (shaded). Glutamine residue
in bold in QQGPPP sequence corresponds to the amino acid that
Table 1. Sequence of Peptide P-C variants and their masses
Protein
ID/peptide
P-C
Measured
monoisotopic
mass (Da)
Acc
numbers
(SwissProt) Proposed seq
Variant 1 4367.2570 Da GRPQGPPQQGGHPR
GPPPQGGRPQGPPQ
Regular 4368.1855 Da P02810 GRPQGPPQQGGHQ
123-166 QGPPPQGGRPQGPP
Variant 2 4369.1696 Da GRPQGPPQQGGHQ
QGPPPQGGRPQGPPwas found to be replaced by E in Variant 2.However, we were unable to completely resolve the
sequence of Variant 1. Although many predicted cleav-
ages were observed by ECD, unique diagnostic product
ions consistent with the hypothesized replacement of
the QQGPPP sequence by PRPPR (Table 4 of Supple-
mentary Material) could not be assigned from the
datasets because there were no fragments produced
within the putative PRPPR substitution sequence. Fur-
ther experiments on samples enriched in this variant
will be necessary to fully resolve the sequence and
unambiguously assign the details of the mass change.
Discussion
High-resolution top-down MS based approaches to
proteomics were first described by McLafferty and
coworkers [26] and have since become a powerful
method to embrace the full complexity of protein struc-
ture [27]. Following this demonstration, software was
developed with a view to automate data analysis. This
was achieved with development of Thrash [28] and
ProSight PTM software [21]. Many of the most abun-
dant proteins in human saliva are proteolytic cleavage
products derived from larger precursors, and many of
these feature proline-rich sequence repeats. While the
physiologic significance of these sequences remains an
interesting question, it is noteworthy that bottom-up
proteomics strategies can report accurately on those
gene products that are present, but poorly on the exact
nature of the processed gene products. Analysis of the
intact proteins using top-down strategies provides a
means to accurately characterize the full diversity of the
human salivary proteome. This study of Peptide P-C, a
small 4371 Da peptide abundant in human saliva,
illustrates a difficult problem in top-down analysis.
In our article, we wondered if the term “top-down”
or “middle-down” was the most appropriate to de-
scribe our work. Referring to the papers where the
“top-down” term was described [26, 29], the most
rigorous definition of a top-down experiment involves
high-resolution measurement of an intact molecular
weight value and direct fragmentation of protein ions in
the gas phase. A new variant method, known as “middle-
down” was recently introduced, which combines the
benefits of limited proteolysis to generate large protein
ces
Calculated
monoisotopic
MW (Da)
Mass
accuracy
(PPM) Observations
PPPGKPQ
PQ
4367.2391 4.2 Replacement of
QQGPPP by PRPPR
PPPPPGKP 4368.1755 2.4 Regular sequence
SPQ
PPPPGKP 4369.1595 2.4 SNP’s at Q14
SPQuen
PPR
GQS
QGP
QGQ
EGPPfragments that are then fragmented by tandem MS [30].
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study lie somewhere in between “top-down” and
“middle-down.” However, our 4–5 kDa polypeptides
are processing products of larger proteins that are
endogenous and functional to the biological system,
i.e., proteases were not added externally for the
purposes of deriving amino acid sequence, as pre-
scribed for a “bottom-up” or “middle-down” proto-
cols. The 4–5 kDa size range is probably a reasonable
lower limit for the “top-down” term because it is not
routine to determine complete sequence information
for a 40–50 amino acid polypeptide from a single
MS/MS experiment (even with ECD/ETD). For all
these reasons, we considered that our experiments
refer to a top-down approach that would, in that case,
embrace all proteins with a mass of 4–5 kDa and
above that have not been further processed for the
Figure 4. Ultra-high-resolution IRMPD spectru
of Peptide P-C (R  750 000). Inserts show produ
at m/z 1120.54, a single satellite peak such as the b
peaks such as the b42-NH3 ion (m/z 1028.51, z 
(filled square)], the regular Peptide P-C sequenc
Tables of assigned product ions for the three for
are shown in Supplementary Materials.purpose of the study.The original suspicion of the presence of Peptide P-C
variants was the result of partial chromatographic sep-
aration and non-overlapping ESI charge state distribu-
tions recorded with a low-resolution mass spectrome-
ter. However, full characterization of each variant
requires identification of unique product ions that un-
ambiguously solve the primary structure. In the case of
PRPs, and Peptide P-C in particular, repeated use of the
same amino acid residues and the presence of sequence
repeats hamper the identification of unique product
ions. Furthermore, the production of internal product
ions under CAD or IRMPD conditions increases assign-
ment ambiguity, again lowering the chances of identi-
fying unique product ions. High-resolution and mass
accuracy helps to limit doubt, but still many ambigu-
ities remain because of identical chemical formulae for
potential assignments of fragment ions. The lack of
products arising from the 5-charged parent ion
ns that contain no shoulders such as the y11 ion
n (m/z 1011.01, z 4), or two additional satellite
Peaks were attributed to Variant 1 [ 0.936 Da,
erisk), and Variant 2 [0.984 Da, (filled circle)].
ith automated and manually extracted peak listm of
ct io
41 io
4).
e (ast
ms winternal fragmentation in ECD experiments is an advan-
riant
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Variant 2 variant could be clearly defined, even though
the experiments were done at ultra-high-resolution (R 
750,000) and with CAD, IRMPD, and ECD fragmentation.
When Variant 2 was investigated, the apparent mass
accuracy of the product ions was lower than expected.
This is assigned this to the fact that the Xtract software
could not all three distributions, and thus incorrect
peaks (e.g., 13C of the regular Peptide P-C instead of the
monoisotopic peak of the deamidated form) were used
for assignments by the ProSight software. A solution to
this problem lies in the modeling of theoretical profiles
to better match data. ProSight was found to be reliable
in the manual mode search but is completely reliant on
Figure 5. ECD MS/MS spectrum of the 5-ch
upper panel shows the full spectrum revealin
resulting from charge neutralization. The low
expanded by 32-fold, showing the low-abundant
show expanded views of z36 and z40 fragmen
revealed the presence of all three variants. Pea
square)], the regular Peptide P-C sequence (a
However, there were no fragment ions in the ECD
of the PRPPR sequence that is postulated for Vathe peak list from Xtract, dictating the need for addi-tional manual processing. Solutions to this problem will
require more highly developed algorithms that attempt
to interpret the entire mass spectrum with capabilities
for de novo sequencing, and not just matching to a
database. Ideally, software for automated assignment of
top-down data needs to consider all possible primary
structure permutations at each residue, with some type
of unbiased iterative process to refine the best match
while taking into account the experimental isotopic
variations.
Since 1971, there have been numerous reports of the
presence of genetic polymorphism in salivary proteins
[31]. Genetic recombination of PRPs leading to a variety
of molecular weight variants were linked to the expres-
parent ion of Peptide P-C (R  100 000). The
additional lower charge states of the parent
anel is the same spectrum with the ordinate
ment ions of interest. Inserts on the upper panel
s where detection of the monoisotopic peaks
ere attributed to Variant 1 [0.936 Da, (filled
k), and Variant 2 [0.984 Da, (filled circle)].
ctrum that unambiguously verified the presence
1.arged
g the
er p
frag
t ion
ks w
steris
spesion of different alleles [22, 23, 32, 33]. In a more specific
876 HALGAND ET AL. J Am Soc Mass Spectrom 2010, 21, 868–877manner, Lyons et al. [34] reported the presence of
insertion/deletion polymorphism within the PRP mul-
tigene family. Variant lengths were shown to coexist
and the result of different numbers of tandem repeats in
the third exons of several individuals. Homologous but
unequal intragenic crossovers seemed to be a general
phenomenon for the PRP genes. In contrast, PRH genes
(Peptide P-C genes) were shown to contain fewer
repeats and no insertion/deletion PRH loci, leading to
the absence of apparent length variants. However since
allelic PRH1 variants were reported, mechanisms other
than unequal pairing were proposed to explain the
inter-individual PRH variations. Indeed, the third exons
of the PRH1 and PRH2 genes were shown to contain
only five tandem repeats but of substantial lengths
differences. Such length differences were proposed to
affect adversely the stability of misaligned DNA strands
and to account for the production of PRH variants.
In addition, Maeda et al. [35] demonstrated that
differential mRNA splicing and post-translational
cleavages could generate a large number of PRPs that
could explain the diversity of PR proteins. In the
particular case of Peptide P-C Variant 1, one can hy-
pothesize that the presence of this variant could derive
from DNA slippage or differential mRNA splicing
leading to the substitution of the GRPQGPPQQG-
GHQQGPPP sequence for the GRPQGPPQQGGH-
PRPPR sequence. This phenomenon can be reduced,
due to the presence of a high sequence homology
between tandem repeats, to the replacement of the
QQGPPP amino acid string from the regular sequence
toward PRPPR sequence (0.936 Da mass difference).
Similarly, SNPs were also reported in salivary proteins
with the exchange of Asp/Asn revealed by cDNA
sequencing. The origin of the heavier form of Peptide
P-C (Variant 2) could be explained by the occurrence of
a SNP rather than from a deamidation event.
The biological role of these variants is obscure. We
identified the three forms of Peptide P-C in several
individuals (five samples from different volunteers).
Apart from the role of PRPs in oral calcium disposition,
relatively little is known about Peptide P-C from a
biological perspective. Recent studies demonstrated
that it can modulate blood glucose levels after feeding
by inducing insulin release and lowering glucagon
levels [15, 16]. Additional studies are needed to eluci-
date the biological significance of each Peptide P-C
variant.
Conclusion
In this study, we demonstrated that unprejudiced sam-
ple analysis using MS and MS/MS techniques or other
approaches is required to discover new protein iso-
forms. Results we obtained also raised the question of
biological compound diversity that could be much
more extended than previously expected. Another im-
portant issue addressed in this paper is related to the
following interrogation: “Are the experiments, method-ologies, instrument capabilities (sensitivity, resolving
power, dynamic range . . . ), and data analyses proce-
dures used sufficient to fully characterize a selected
sample?” This point is of particular importance for the
search of new biomarkers in pathologies or to obtain an
exact view of protein diversity and function [36].
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